Somatuline

Loew

Pharma

Ipsen CEO 'not at all afraid' of Big Pharma in rare diseases

Ipsen is "agnostic" in terms of rare disease indications, but there’s one field CEO David Loew doesn't want to enter just yet.

Angus Liu Jan 18, 2023 10:55am

Ipsen

Dire straits detailed for Epizyme before buyout by Ipsen

Jul 13, 2022 8:46am

Ipsen CEO David Loew

Ipsen snaps up Epizyme and cancer drug Tazverik for $247M

Jun 27, 2022 10:20am

People shaking hands across a desk that has computer and papers on it

Ipsen starts $66M Somatuline autoinjector project

Mar 21, 2022 7:35am